1200+ US adults with SMA have
been treated with SPINRAZA.*

1200 LAUREN

*Based on commercial patients in the US (including
Puerto Rico ) through December 2019.

OVER 3 YEARS OF
REAL-WORLD EXPERIENCE

Now more than 3000 individuals with SMA have been
treated with SPINRAZA in the US.

individuals
are adults

individuals who started on SPINRAZA remain on treatment

Based on commercial patients in the US (including Puerto Rico ) through December 2019.

Clinical overview


SPINRAZA has been studied in the largest clinical trial conducted to date in spinal muscular atrophy (SMA) and evaluated in individuals across a broad range of SMA types and levels of function. Clinical trials enrolled patients aged 3 days to 16 years old and included patients with later-onset SMA.

Clinical outcomes may vary in patients older than the studied population.

Lauren, an adult with Type 3 SMA

CHERISH and CS2/CS12

Later-onset SMA

Multiple studies of individuals with Types 2 and 3 SMA aged 2 to 16 years old

See motor function results

QUESTIONS + ANSWERS

Did motor function improve in people on SPINRAZA with later-onset SMA?

Improvements in motor function were seen over 15 months in CHERISH, a well-controlled clinical study of 126 nonambulatory individuals aged 2 to 9 years old. Motor skills such as sitting, rolling, and arm strength were measured primarily by the Hammersmith Functional Motor Scale—Expanded (HFMSE) and supported by the Revised Upper Limb Module (RULM).

The long-term effects of SPINRAZA were evaluated in the CS2/CS12 study over a 3-year period (1050 days) in 11 individuals with Type 2 and 17 individuals with Type 3 SMA ranging from 2 to 16 years old. CS2/CS12 was an open-label study and all individuals received SPINRAZA. Limitations included differences in dosing compared with the approved regimen and the lack of an untreated group.

Some individuals taking SPINRAZA improved or maintained motor function over nearly 3 years, regardless of their level of function before starting treatment (baseline).

Go to our later-onset efficacy page to read about the results of the CHERISH and CS2/CS12 clinical studies, which evaluated the efficacy of SPINRAZA for later-onset SMA.

Who is SPINRAZA for?

SPINRAZA is indicated for both adults and children with SMA.

How many adults with SMA have been treated with SPINRAZA?

Over 1200 adults with SMA have been treated with SPINRAZA in the US,* and a total of over 10,000 infants, children, and adults with SMA have been treated with SPINRAZA worldwide, including early access and commercial patients, as well as clinical trial participants (through December 2019).

*Based on commercial patients in the US (including Puerto Rico) through December 2019.

How can I find an available treatment center near me?

The SPINRAZA Treatment Locator is a user-friendly search engine on SPINRAZA.com that can help you find the HCPs and treatment facilities closest to you that may be able to administer SPINRAZA. The search results show an interactive map with information about HCPs and facilities that have chosen to be listed.

Biogen is committed to making sure that individuals treated with SPINRAZA and their families are able to access treatment. We're committed to continually adding new treatment sites to our growing list. Before choosing a treatment center, be sure to speak with your primary HCP.

To get started, visit the SPINRAZA Treatment Center Locator.

YOU + YOUR SUPPORT SYSTEM

Learn how SMA360° can help you navigate the cost of treatment through insurance support and financial assistance.§

§SMA360° services from Biogen are available only to those who have been prescribed SPINRAZA.

SMA360° is intended for US residents only.

SPINRAZA STORIES

Hear from some of the 1200+ US adults on SPINRAZA

Stay connected

Sign up to learn about the latest news, support information, and upcoming events.

Valid Email Required

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

This information is not intended to replace discussions with your healthcare provider.


INDICATION

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.